Newron Pharmaceuticals S.p.A.
NWPHF
Get informed when a big investor buys or sells
+ FollowMarket Cap$416.12M
Close$
$-19.26
196.3% downside
Current Fair Value
196.3% downsideOvervalued by 196.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $416.12 Million |
|---|---|
| Enterprise Value | $439.13 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.66 |
| Beta | 0.74 |
| Outstanding Shares | 20,527,017 |
Return
| Return on Equity | 35.45% |
|---|---|
| Return on Assets | -10.28% |
| Return on Invested Capital | 43.81% |
Valuation & Multiples
| P/E Ratio | -5.59 |
|---|---|
| PEG | -0.03 |
| Price to Sales | 6.67 |
| Price to Book Ratio | -20.0 |
| Enterprise Value to Revenue | 6.25 |
| Enterprise Value to EBIT | 35.99 |
| Enterprise Value to Net Income | -106 |
| Total Debt to Enterprise | 0.09 |
| Debt to Equity | -3.34 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
September 22, 2026
EPS Estimate
$-0.80
Average shareholder expectationRevenue Estimate
$4.57 M
Average shareholder expectationNext Earnings Call
Expected Date
March 16, 2027
EPS Estimate
$-0.86
Average shareholder expectationRevenue Estimate
$8.88 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Newron Pharmaceuticals S.p.A.
22 employees
CEO: Stefan Weber Newron Pharmaceuticals S.p.A. is a biopharmaceutical company in the clinical development phase, focused on discovering and advancing novel therapeutic solutions for central and peripheral nervous system disorders, as well as pain managem...